Actualités en cancérologie digestive à l’UEGW 2016

2017 ◽  
Vol 47 (1) ◽  
pp. 36-38
Author(s):  
T. Lecomte ◽  
E. Vaillant
Keyword(s):  
Cancérologie Digestive

scholarly journals Cancer des voies biliaires : les tables de la loi. Les recommandations du Thésaurus National de Cancérologie Digestive

2009 ◽  
Vol 1 (2) ◽  
pp. 112
Author(s):  
David Malka ◽  
Olivier Chapet ◽  
Laurence Chiche ◽  
Thierry De Baere ◽  
Clarisse Dromain ◽  
...  
Keyword(s):  
Voies Biliaires ◽  
Cancérologie Digestive ◽  
Cancer Des Voies Biliaires

En cancerologie digestive : le pet-ct risque-t-il de supplanter le scanner abdomino-pelvien

2006 ◽  
Vol 87 (10) ◽  
pp. 1281
Author(s):  
O. Pellet ◽  
F. Cotton ◽  
F. Giammarile ◽  
P.J. Valette
Keyword(s):  
Pet Ct ◽  
Cancérologie Digestive

Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803

2004 ◽  
Vol 22 (21) ◽  
pp. 4319-4328 ◽  
Author(s):  
Olivier Bouché ◽  
Jean Luc Raoul ◽  
Franck Bonnetain ◽  
Marc Giovannini ◽  
Pierre Luc Etienne ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Progression Free Survival ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Survival Times ◽  
Multicenter Phase ◽  
Independent Expert ◽  
Phase Iii Study ◽  
Cancérologie Digestive

Purpose To determine the efficacy and safety of a biweekly regimen of leucovorin (LV) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study. Patients and Methods One hundred thirty-six patients (two were ineligible) were enrolled onto the randomized multicenter phase II trial. Patients received LV 200 mg/m2 (2-hour infusion) followed by FU 400 mg/m2 (bolus) and FU 600 mg/m2 (22-hour continuous infusion) on days 1 and 2 every 14 days (LV5FU2; arm A), LV5FU2 plus cisplatin 50 mg/m2 (1-hour infusion) on day 1 or 2 (arm B), or LV5FU2 plus irinotecan 180 mg/m2 (2-hour infusion) on day 1 (arm C). Results The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively. Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively. Conclusion Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.

Sign in / Sign up

Export Citation Format

Share Document